Our nationally recognized Life Sciences practice can help you navigate the issues associated with the development and commercialization of innovative medical products and services.
A Full-Service Practice
We have substantial experience throughout all areas of the industry including on behalf of biotechnology, pharmaceutical, medical device and healthcare services companies, medical-research institutes and patient organizations. Our international life science client base consists of companies in all stages of development, from startups to Fortune 50 companies. Drawing on the talents of a wide variety of professionals, many of whom have had previous careers as scientists, MDs and high-ranking government officials, we can help you to navigate the complex waters associated with the development, approval, commercialization, reimbursement and coverage of innovative medical products and services.
Why Foley Hoag?
public and private clients, representing all facets of the Life Sciences industry
in life sciences-related deal activity for clients over the last 10 years
of the firm’s work focused on the Life Science community, making it our largest sector
We represented Ginkgo Bioworks in its collaboration with Merck to engineer up to four enzymes for use as biocatalysts in Merck’s active pharmaceutical ingredient manufacturing efforts
Deals & Cases
We represented biotechnology ecosystem company Alloy Therapeutics in its $42 million Series D financing
Deals & Cases
We advised regenerative medicine company Satellite Bio in its $110 million Seed and Series A financings
Deals & Cases
We advised H.I.G. BioHealth Partners and Accelmed Partners as new investors and co-leads in the $52 million upsized Series B financing of digital therapeutics company Click Therapeutics
Deals & Cases
We represented GreenLight Biosciences in its $1.5 billion SPAC business combination with Environmental Impact Acquisition Corp.
Awards & Accolades
Chambers USA 2022
Ranked as a leading law firm in Chambers USA 2022 in a variety of areas, including Life Sciences, Corporate/M&A, IP and Venture Capital Investment
The Legal 500
Recognized as a leader in Healthcare: Life Sciences and M&A: Middle-Market (sub-$500 million) by The Legal 500 United States 2022
Managing Intellectual Property
Managing Intellectual Property named Barbara Fiacco to its 2022 Top 250 Women in IP list, recognizing female IP practitioners in private practice across the globe
U.S. News - Best Lawyers
Recognized nationally for Biotechnology, Litigation - Intellectual Property, Patent and Venture Capital law in 2023 U.S. News - Best Lawyers® “Best Law Firms;” overall, Foley Hoag is ranked in 20 national & 37 regional categories
LMG Life Sciences
Five Foley Hoag partners recognized as leaders in their field; Partner Donald Ware was named 2021 General Patent Litigator of the Year – New England, and Partner Hemmie Chang was a 2019 inductee into the LMG Life Sciences Hall of Fame
One of only six Massachusetts law firms ranked in Tier 1 for M&A by IFLR1000 2021; shortlisted for Massachusetts Law Firm of the Year 2021
IAM Licensing 250
Named to IAM Licensing 250 - The World’s Leading Patent Licensing Lawyers list as well as to the Patent and Litigation 250 - The World’s Leading Patent Litigators
50 lawyers listed in the 2023 Best Lawyers in America guide, a ranking based on peer review
We advise early stage to global leaders of drug, biological and medical device companies on a broad range of health policy matters impacting novel technologies with a particular expertise on Medicare coverage, coding and payment determinations.
Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK," you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you.
If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Foley Hoag.